Heba Allam
Concepts (121)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 2 | 2017 | 474 | 0.810 |
Why?
| N-Acetylglucosaminyltransferases | 2 | 2017 | 19 | 0.750 |
Why?
| Neoplastic Stem Cells | 2 | 2017 | 104 | 0.660 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 206 | 0.650 |
Why?
| Software | 1 | 2020 | 297 | 0.610 |
Why?
| Receptors, Notch | 1 | 2017 | 27 | 0.600 |
Why?
| Carcinoma | 1 | 2017 | 154 | 0.550 |
Why?
| Neoplasms | 2 | 2021 | 1321 | 0.540 |
Why?
| Neoplasm Proteins | 1 | 2017 | 360 | 0.500 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 270 | 0.460 |
Why?
| Carcinoma, Hepatocellular | 3 | 2013 | 203 | 0.400 |
Why?
| Signal Transduction | 2 | 2021 | 1751 | 0.400 |
Why?
| Health Level Seven | 1 | 2021 | 7 | 0.400 |
Why?
| Ribosome Subunits, Small, Eukaryotic | 1 | 2009 | 2 | 0.370 |
Why?
| Genes, src | 1 | 2009 | 4 | 0.370 |
Why?
| Peptide Chain Initiation, Translational | 1 | 2009 | 15 | 0.360 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2009 | 18 | 0.360 |
Why?
| Image Processing, Computer-Assisted | 1 | 2021 | 256 | 0.360 |
Why?
| Electronic Health Records | 1 | 2021 | 203 | 0.330 |
Why?
| Cell Transformation, Neoplastic | 1 | 2009 | 200 | 0.330 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 490 | 0.320 |
Why?
| Glycosylation | 2 | 2017 | 112 | 0.280 |
Why?
| Gender Identity | 1 | 2015 | 26 | 0.270 |
Why?
| Multiple Myeloma | 4 | 2021 | 3049 | 0.270 |
Why?
| Data Mining | 1 | 2015 | 38 | 0.270 |
Why?
| Hepacivirus | 3 | 2013 | 127 | 0.260 |
Why?
| Hepatitis, Autoimmune | 1 | 2005 | 29 | 0.250 |
Why?
| Autoantibodies | 1 | 2005 | 135 | 0.240 |
Why?
| Gene Expression Profiling | 3 | 2021 | 1141 | 0.240 |
Why?
| Hepatitis C, Chronic | 1 | 2005 | 89 | 0.240 |
Why?
| Social Media | 1 | 2015 | 104 | 0.230 |
Why?
| Mutation | 2 | 2020 | 1504 | 0.230 |
Why?
| Plasma Cells | 2 | 2021 | 239 | 0.220 |
Why?
| Algorithms | 2 | 2021 | 697 | 0.210 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 151 | 0.210 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2021 | 50 | 0.200 |
Why?
| Evolution, Molecular | 1 | 2021 | 103 | 0.190 |
Why?
| Lymphoma, Follicular | 1 | 2020 | 30 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 275 | 0.180 |
Why?
| Gene Dosage | 1 | 2020 | 92 | 0.180 |
Why?
| Genome, Human | 1 | 2020 | 131 | 0.180 |
Why?
| Humans | 13 | 2021 | 54304 | 0.170 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 92 | 0.170 |
Why?
| Genomics | 1 | 2020 | 313 | 0.160 |
Why?
| Tissue Banks | 1 | 2017 | 8 | 0.160 |
Why?
| Female | 7 | 2020 | 28457 | 0.150 |
Why?
| Mice, Inbred NOD | 1 | 2017 | 99 | 0.150 |
Why?
| Cell Line, Tumor | 3 | 2017 | 1551 | 0.150 |
Why?
| Ovary | 1 | 2017 | 105 | 0.150 |
Why?
| Neoplasm Recurrence, Local | 1 | 2021 | 645 | 0.150 |
Why?
| Tumor Burden | 1 | 2017 | 141 | 0.150 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2017 | 219 | 0.150 |
Why?
| RNA Interference | 1 | 2017 | 195 | 0.150 |
Why?
| RNA, Small Interfering | 2 | 2014 | 253 | 0.150 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 294 | 0.140 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 183 | 0.140 |
Why?
| Kaplan-Meier Estimate | 1 | 2017 | 514 | 0.140 |
Why?
| Glycomics | 1 | 2014 | 9 | 0.130 |
Why?
| Fatty Acids, Monounsaturated | 1 | 2013 | 15 | 0.120 |
Why?
| Microtubules | 1 | 2013 | 57 | 0.120 |
Why?
| Tandem Mass Spectrometry | 1 | 2014 | 248 | 0.110 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2014 | 377 | 0.110 |
Why?
| Virus Replication | 1 | 2013 | 143 | 0.110 |
Why?
| Indoles | 1 | 2013 | 289 | 0.100 |
Why?
| RNA, Viral | 1 | 2011 | 141 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2020 | 1248 | 0.090 |
Why?
| Cell-Free System | 1 | 2009 | 16 | 0.090 |
Why?
| RNA Caps | 1 | 2009 | 10 | 0.090 |
Why?
| 5' Untranslated Regions | 1 | 2009 | 33 | 0.090 |
Why?
| Data Collection | 1 | 2021 | 319 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2021 | 323 | 0.090 |
Why?
| HeLa Cells | 1 | 2009 | 291 | 0.080 |
Why?
| Neoplasm Metastasis | 1 | 2009 | 252 | 0.080 |
Why?
| Stress, Physiological | 1 | 2009 | 194 | 0.080 |
Why?
| Tomography, X-Ray Computed | 1 | 2021 | 1222 | 0.070 |
Why?
| Prognosis | 2 | 2021 | 2126 | 0.060 |
Why?
| Autoimmunity | 1 | 2005 | 38 | 0.060 |
Why?
| Viral Load | 1 | 2005 | 86 | 0.060 |
Why?
| Language | 1 | 2015 | 137 | 0.060 |
Why?
| Magnetic Resonance Imaging | 1 | 2021 | 1616 | 0.060 |
Why?
| Animals | 2 | 2017 | 14402 | 0.060 |
Why?
| Genotype | 1 | 2005 | 600 | 0.060 |
Why?
| Liver | 2 | 2011 | 1226 | 0.060 |
Why?
| Syndecan-1 | 1 | 2021 | 82 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 134 | 0.050 |
Why?
| Remission Induction | 1 | 2021 | 222 | 0.050 |
Why?
| Diagnosis, Differential | 1 | 2005 | 1143 | 0.050 |
Why?
| Recurrence | 1 | 2021 | 692 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 217 | 0.040 |
Why?
| Male | 3 | 2020 | 27335 | 0.040 |
Why?
| Disease Progression | 1 | 2021 | 915 | 0.040 |
Why?
| Survival Rate | 1 | 2020 | 954 | 0.040 |
Why?
| Middle Aged | 2 | 2020 | 13076 | 0.040 |
Why?
| Cell Proliferation | 1 | 2021 | 1097 | 0.040 |
Why?
| Adult | 2 | 2020 | 14189 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2020 | 2389 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2013 | 35 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1060 | 0.030 |
Why?
| Adolescent | 1 | 2005 | 6896 | 0.030 |
Why?
| Risk Factors | 1 | 2021 | 3934 | 0.030 |
Why?
| Antiviral Agents | 1 | 2013 | 188 | 0.030 |
Why?
| Down-Regulation | 1 | 2013 | 388 | 0.030 |
Why?
| Hepatocytes | 1 | 2013 | 214 | 0.030 |
Why?
| Keratin-19 | 1 | 2011 | 2 | 0.030 |
Why?
| Replicon | 1 | 2011 | 7 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2011 | 76 | 0.030 |
Why?
| Cell Survival | 1 | 2013 | 657 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2011 | 166 | 0.020 |
Why?
| Mice, Nude | 1 | 2011 | 284 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 206 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2011 | 371 | 0.020 |
Why?
| Hepatitis C | 1 | 2011 | 94 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 674 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 474 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 547 | 0.020 |
Why?
| RNA, Messenger | 1 | 2011 | 1203 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2011 | 352 | 0.020 |
Why?
| Aged | 1 | 2020 | 10054 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1300 | 0.020 |
Why?
| Mice | 1 | 2011 | 6428 | 0.010 |
Why?
|
|
Allam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|